Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 9/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.56 |
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404524 | 0.93 | AURKB (0.59) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL14507416 | 0.86 | AURKA (0.64) | AURKAAURKBFYNPTK6CHEK1 | |
| SCHEMBL12404532 | 0.86 | AURKA (0.64) | AURKAAURKBPTK6CHEK1FLT3 | |
| SCHEMBL12404525 | 0.85 | AURKA (0.65) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL14536769 | 0.85 | AURKB (0.62) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL12404535 | 0.84 | AURKA (0.63) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL14538360 | 0.82 | AURKB (0.59) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL12404526 | 0.82 | AURKB (0.58) | AURKAAURKBPTK6CHEK1 | |
| SCHEMBL14507417 | 0.82 | AURKA (0.58) | AURKAAURKBCHEK1 | |
| SCHEMBL12404523 | 0.81 | AURKA (0.57) | AURKAAURKBPTK6CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | AURKA 40/4885AURKB 27/4885MAPKAPK5 205/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKA 41/4885AURKB 138/4885MAPKAPK5 61/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885AURKB 24/4885MAPKAPK5 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.